How to Correctly Treat Takeda Mobosetinib/Mobosetinib Delisting

Mobocertinib, also known as mobocertinib or Mobocertinib, is a drug used to treat non-small cell lung cancer. It belongs to a class of drugs called tyrosine kinase inhibitors, which prevent the growth and spread of tumor cells by inhibiting the activity of certain kinases. Mobosetinib is mainly used for patients with advanced non-small cell lung cancer who are positive for EGFR gene mutations. This gene mutation is relatively common in some patients.

The delisting of Takeda’s moboxetinib is an important event and we should treat it correctly. Drug development and marketing is a complex process involving multiple links and factors. Although mobotinib has shown certain efficacy in clinical trials, there are also some safety and efficacy issues. Therefore, there is a trend of delisting Moboxetinib in the United States, but there is no news of delisting in China yet. The withdrawal of a drug from the market does not mean that there are no other effective treatment options. Discuss possible alternative treatments with your doctor to see if there are other medications or treatment options that may be appropriate for your patient.

Mobosetinib The original drug has been launched in China, but it is not included in the medical insurance. The price of the common specification 40mg*112 pills per box is about 40,000 yuan, which is very high. The Hong Kong clinical version specification 40mg*30 pills per box is priced at more than 7,000 yuan (the price may fluctuate due to exchange rates). Generic drugs of Mobotinib have also been put on the market for sale overseas. Its pharmaceutical ingredients are basically the same as those of the original drugs at home and abroad. For example, the production specifications of Laos Pharmaceutical Factory 40mg*120 pills per box may be more than 4,000 yuan (the price may fluctuate due to the exchange rate), and the price is relatively cheap.